{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:22Z","timestamp":1793212162189,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cgh.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:31:04Z","timestamp":1746531064000},"page":"2376-2398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review With Meta-analysis"],"prefix":"10.1016","volume":"23","author":[{"given":"Sudheer K.","family":"Vuyyuru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Shaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailish","family":"Honap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotus","family":"Alphonsus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theshani Amalka","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Alajmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parambir S.","family":"Dulai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.03.007_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.03.007_bib2","first-page":"375","article-title":"Cortisone in ulcerative colitis; preliminary report on a therapeutic trial","volume":"2","author":"Truelove","year":"1954","journal-title":"BM J"},{"issue":"Suppl 3","key":"10.1016\/j.cgh.2025.03.007_bib3","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.03.007_bib4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Clinical Practice Guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.03.007_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/2050640620977405","article-title":"Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: a multicentre cohort study","volume":"9","author":"Festa","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2025.03.007_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","article-title":"Acute severe ulcerative colitis management: unanswered questions and latest insights","volume":"9","author":"Rivi\u00e8re","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.03.007_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MEG.0000000000000568","article-title":"Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review","volume":"28","author":"Thorne","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.03.007_bib8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gut.38.6.905","article-title":"Predicting outcome in severe ulcerative colitis","volume":"38","author":"Travis","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.03.007_bib9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/ibd\/izac134","article-title":"Trends in medical management of moderately to severely active ulcerative colitis: a nationwide retrospective analysis","volume":"29","author":"Yuan","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.03.007_bib10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/apt.16202","article-title":"Colectomy rates for ulcerative colitis in England 2003-2016","volume":"53","author":"Worley","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.03.007_bib11","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.03.007_bib12","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.03.007_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gutjnl-2016-313060","article-title":"Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab","volume":"67","author":"Laharie","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.03.007_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.03.007_bib15","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/gutjnl-2024-332489","article-title":"Acute severe ulcerative colitis trials: the past, the present and the future","volume":"73","author":"Honap","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.03.007_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.cgh.2025.03.007_bib18","author":"Buchan"},{"key":"10.1016\/j.cgh.2025.03.007_bib19","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.cgh.2025.03.007_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2025.03.007_bib21","author":"Wells"},{"key":"10.1016\/j.cgh.2025.03.007_bib22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2025.03.007_bib40","doi-asserted-by":"crossref","first-page":"156407","DOI":"10.1155\/2011\/156407","article-title":"Short-and long-term clinical outcomes of infliximab in fulminant ulcerative colitis","volume":"2011","author":"Florholmen","year":"2011","journal-title":"Ulcers"},{"key":"10.1016\/j.cgh.2025.03.007_bib41","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1016\/j.cgh.2022.02.055","article-title":"Corticosteroids and mesalamine versus corticosteroids for acute severe ulcerative colitis: a randomized controlled trial","volume":"20","author":"Ben-Horin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.03.007_bib42","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomized controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.03.007_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.15592","article-title":"Systematic review with meta-analysis: mortality in acute severe ulcerative colitis","volume":"51","author":"Dong","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.03.007_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ajg.2016.7","article-title":"Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.03.007_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00042737-200501000-00016","article-title":"Ciclosporin use in acute ulcerative colitis: a long-term experience","volume":"17","author":"Campbell","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.03.007_bib26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cgh.2025.03.007_bib27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.03.007_bib28","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s10620-018-5407-7","article-title":"Systematic review: efficacy and safety of accelerated induction regimes in infliximab rescue therapy for hospitalized patients with acute severe colitis","volume":"64","author":"Sebastian","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2025.03.007_bib29","article-title":"P872 PREDICT UC: optimising infliximab induction therapy for acute severe ulcerative colitis \u2013 a randomised controlled trial","volume":"18","author":"Choy","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.03.007_bib30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/flgastro-2019-101277","article-title":"Practice pattern variability in the management of acute severe colitis: a UK provider survey","volume":"11","author":"Sebastian","year":"2020","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.cgh.2025.03.007_bib31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.03.007_bib32","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review","volume":"17","author":"Gisbert","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.03.007_bib33","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/ibd\/izaa318","article-title":"Clinical and mechanistic characteristics of current JAK inhibitors in IBD","volume":"27","author":"Pippis","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.03.007_bib34","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.14309\/00000434-201810001-00626","article-title":"Baseline albumin level is not a significant predictor of tofacitinib efficacy in patients with ulcerative colitis: results of multivariate exposure-response analysis: 626","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.03.007_bib35","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.03.007_bib36","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.03.007_bib37","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ibd\/izae191","article-title":"Upadacitinib for acute severe ulcerative colitis: a systematic review","volume":"31","author":"Damianos","year":"2025","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2025.03.007_bib38","article-title":"DOP46 Tofacitinib for hospitalized acute severe ulcerative colitis: the TRIUMPH study","volume":"18","author":"Narula","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.03.007_bib39","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","article-title":"Global hospitalization trends for Crohn's disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses","volume":"21","author":"Buie","year":"2023","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525003295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525003295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:16:38Z","timestamp":1783628198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525003295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1542356525003295"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.03.007","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review With Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}